Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iris

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Iris. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-005464-14 Sponsor Protocol Number: LucNVG0108 Start Date*: 2009-03-30
    Sponsor Name:Prof. Salvatore Grisanti
    Full Title: An open label, prospective, monocenter, prove of concept study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rube...
    Medical condition: Rubeosis and Neovascular Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039291 Rubeosis iridis LLT
    9.1 10062891 Neovascular glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003061-28 Sponsor Protocol Number: PDS_Version_1.2 Start Date*: 2015-09-08
    Sponsor Name:Vienna Institute for Research in Ocular Surgery
    Full Title: Effect of selective alpha 1A receptor antagonists on the iris dilator muscle
    Medical condition: Effect of selective alpha 1A receptor antagonists on the iris dilator muscle
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003885-15 Sponsor Protocol Number: OMS302-ILR-006 Start Date*: 2014-01-06
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Int...
    Medical condition: Intraocular Lens Replacement (ILR) in subject at high risk for Intraoperative Floppy Iris Syndrome (IFIS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10054771 Intraocular lens replacement LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000585-21 Sponsor Protocol Number: prot RG 1 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal Victoria Eye and Ear hospital
    Full Title: Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma.
    Medical condition: Rubeotic glaucoma secondary to ischaemic proliferative retinopathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004826-10 Sponsor Protocol Number: SPRA1002 Start Date*: 2006-11-02
    Sponsor Name:Moorfields Eye Hospital
    Full Title: An observational case series to assess the effects of intravitreal Bevacizumab on eyes with neovascular glaucoma
    Medical condition: Neovascular Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062891 Neovascular glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002237-20 Sponsor Protocol Number: ATS K021 Start Date*: 2006-08-21
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCA
    Medical condition: Type 2 diabetic patients treated with oral agents except PPAR gamma agonists and / or patients with insulin resistance measured by IRIS score > 50 with stable coronary artery disease and supposed e...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004501-27 Sponsor Protocol Number: 2183/2019 Start Date*: 2021-01-28
    Sponsor Name:Medical University of Vienna
    Full Title: Perioperative analgesia in children undergoing ophthalmic surgery
    Medical condition: perioperative analgesia
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003481-13 Sponsor Protocol Number: NEAT44 Start Date*: 2019-01-15
    Sponsor Name:NEAT ID Foundation
    Full Title: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter ...
    Medical condition: Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Ongoing) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003064-36 Sponsor Protocol Number: DEF_Version_1.2 Start Date*: 2015-11-10
    Sponsor Name:Vienna Institute for Research in Ocular Surgery
    Full Title: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Medical condition: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002010-38 Sponsor Protocol Number: SC3-90049-001 Start Date*: 2005-11-21
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson D...
    Medical condition: Advanced Parkinson´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002456-18 Sponsor Protocol Number: 758-CL-010 Start Date*: 2006-04-21
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF A FOUR-WEEK TREATMENT WITH YM758 IN SUBJECTS WITH STABLE ANGINA.
    Medical condition: Stable angina pectoris
    Disease: Version SOC Term Classification Code Term Level
    8.0 10049194 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005546-23 Sponsor Protocol Number: IRIS:IND#64,622 Start Date*: 2009-11-05
    Sponsor Name:Yale University School of Medicine
    Full Title: The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ische...
    Medical condition: Insulin resistance in patients who have had a stroke or transient ischaemic attack
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004108-23 Sponsor Protocol Number: 17097AB-AS Start Date*: 2018-10-09
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Low-dose atropine eye drops to reduce progression of myopia in children: a multi-centre placebo controlled randomised trial in the United Kingdom (CHAMP UK)
    Medical condition: Myopia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002562-39 Sponsor Protocol Number: CL2-78989-018 Start Date*: 2013-10-10
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.
    Medical condition: Schnitzler syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000354-11 Sponsor Protocol Number: ABR47613 Start Date*: 2021-04-30
    Sponsor Name:Radboud UMC
    Full Title: The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects
    Medical condition: Dependence on opiate narcotics
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005475-17 Sponsor Protocol Number: CL3-16257-067 Start Date*: 2008-01-04
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to ...
    Medical condition: Stable angina pectoris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10049194 Stable angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) BE (Completed) FI (Completed) GB (Prematurely Ended) HU (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001013-39 Sponsor Protocol Number: PTC124-GD-028-ANI Start Date*: 2022-04-14
    Sponsor Name:PTC Therapeutics, Inc
    Full Title: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
    Medical condition: Nonsense Mutation Aniridia
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-004884-29 Sponsor Protocol Number: PSt012021 Start Date*: 2022-03-16
    Sponsor Name:Pharma Stulln GmbH
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Dose Finding Study of 0.05%, 0.025%, 0.01% and 0.005% Atropine Eye Drops to inhibit myopia progression in children in a European population
    Medical condition: Myopia progression in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:08:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA